# US 8,771,707 B2 · Botulinum neurotoxin E receptors and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,771,707 B2
- Document ID: US8771707B2
- Status: Granted
- Kind: B2
- Application number: 12/569,905
- Filed: 2009-09-30
- Published: 2010-04-29
- Granted: 2014-07-08
- Earliest claimed: 2008-09-30
- Assignees: Wisconsin Alumni Research Foundation
- Applicants: Edwin R. Chapman; Min Dong
- Inventors: Edwin R. Chapman; Min Dong
- Web page: https://patentgrep.com/patent/US8771707B2

## CPC

- C07K 14/473: {alpha-Glycoproteins}
- A61P 25/00: Drugs for disorders of the nervous system
- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- C07K 16/18: against material from animals or humans
- G01N 33/5058: {Neurological cells}
- G01N 2500/02: Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

An isolated polypeptide comprising an amino acid sequence selected from amino acids 506-582 of SV2A, wherein position 573 is N and is glycosylated, or amino acids 449-525 of SV2B, wherein position 516 is N and is glycosylated. The present invention also provides an antibody that binds specifically to the polypeptide, an isolated nucleic acid comprising a polynucleotide that encodes the polypeptide; a method for reducing BoNT/E toxicity in an animal; a method for identifying an agent that blocks or inhibits binding between BoNT/E and an SV2A or SV2B protein; a method for monitoring synaptic vesicle endo- or exocytosis, a method for specifically delivering a chemical entity to a cell which has a specific receptor to a BoNT toxin. Also provided are a chimeric toxin for targeting a proteolytic domain of a toxin to a cell, the chimeric toxin comprising a catalytic or proteolytic domain of the BoNT toxin, and a ligand or a fragment thereof for a non-BoNT receptor on the cell; a method for targeting a proteolytic domain of a BoNT toxin to a cell, an isolated non-neuronal cell comprising a BoNT toxin receptor; and a method for screening for an inhibitor of a BoNT toxin.

## Claims

### Claim 1

A method for reducing botulinum neurotoxin E (BoNT/E) toxicity in an animal comprising administering to the animal a synaptic vesicle membrane protein 2A (SV2A) or synaptic vesicle membrane protein 2B (SV2B) polypeptide, wherein the SV2A polypeptide is at least 90% identical to SEQ ID NO:4, and has a glycosylated N residue at position 573, and wherein the SV2B polypeptide comprises the amino acid sequence set forth as SEQ ID NO:7 and has a glycosylated N at position 516.

### Claim 2 (depends on 1)

The method of claim 1, wherein the animal is a mammal.

### Claim 3 (depends on 2)

The method of claim 2, wherein the mammal is a human.

### Claim 4 (depends on 1)

The method of claim 1, wherein the SV2A polypeptide comprises an amino acid sequence that is at least 90% identical to residues 506-582 of the amino acid sequence set forth as SEQ ID NO:4.

### Claim 5 (depends on 1)

The method of claim 1, wherein the SV2A polypeptide comprises the sequence set forth as residues 506-582 of the amino acid sequence set forth as SEQ ID NO:4.

### Claim 6 (depends on 1)

The method of claim 1, wherein the polypeptide is a full length SV2A or SV2B polypeptide.